This summary was created by AI, based on 2 opinions in the last 12 months.
Royalty Pharma plc, trading under the symbol RPRX-Q, is recognized as a leading entity in the pharmaceutical royalty sector, where it partners with prominent companies like Bristol-Myers to finance drug development in exchange for future royalties. Analysts highlight the recent success of monetizing an investment yielding a $230 million return, significantly contributing to debt reduction and enabling share buybacks. The company's valuation metrics indicate it trades at a compelling earnings multiple, with a robust return on equity, making it an attractive option for investors focused on dividend yield and growth potential. Analysts suggest setting a stop-loss and indicate significant upside potential, reinforcing their positive outlook on the stock's performance in the near term.
Royalty Pharma plc is a American stock, trading under the symbol RPRX-Q on the NASDAQ (RPRX). It is usually referred to as NASDAQ:RPRX or RPRX-Q
In the last year, there was no coverage of Royalty Pharma plc published on Stockchase.
Royalty Pharma plc was recommended as a Top Pick by on . Read the latest stock experts ratings for Royalty Pharma plc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Royalty Pharma plc In the last year. It is a trending stock that is worth watching.
On 2025-03-06, Royalty Pharma plc (RPRX-Q) stock closed at a price of $33.28.
We reiterate RPRX as a TOP PICK. The company is the largest holder of pharma based royalties, providing late stage funding for forward cash royalties. The company just monetized a recent investment that netted $230 million -- a 76% return on investment -- allowing for a pay down in debt, continuation in share buy backs, and further product development. The company trades at 8x earnings, 1.8x book and supports a ROE of 24%. We recommend trailing up the stop (from $22) to $26, looking to achieve $40 -- upside potential of 25%. Yield 2.6%